BioVaxys Technology Corp. C.BIOV

BIOV Papilocare

[ChaseAckland]

Been taking a look at the numbers for BIOV and Papilocare potenital.  Reading from prior PR's they are looking to get FDA approval as a device hopefully this year (same as in the EU, where it is approved and being marketed, which increases liklihood of US device approval).  Per the recent company presentation at GCFF, this could be a $30M-$50M product for BIOV.  But...once launched as a device, no doubt they will look at new formulations/indications etc. and seek FDA approval for a follow-on "Papilocare+" as a therapeutic----this will command much higher price and revenue.   $150M-$300M is realistic.  With this,Covid-t and the EU ovarian cancer clinical study, 9 or so months from now this I think will be flying.

[SnowBall123]

Didn't know the "Papilocare+" part, where did it mention?

[ChaseAckland]

Earlier this year BIO entered a partnership with Procare, a pharmaco in Spain, to codevelop and market BIOV's ovarianc cancer vaccine.  The deal included BIOV having right of refusal to market Papilocare in the US.  That produce is approved and marketed already in Europe, waiting to hears from FDA in the US.  Here is the link to the press release  https://www.prnewswire

[SnowBall123]

Yes we all aware of that, the Papilocare, what about the "Papilocare+" ?

[ChaseAckland]

Sorry!  "Papilocare+" is my speculation on overall strategy.   If they get FDA approval as a device (which is likely, as its approved in EU as a device) they can market it w/o need for a prescription so it will be distributed via doctor offices, pharmacies, chain stores, etc. The PALOMA study done by Procare showed very nice efficacy on cervical lesions and nice effect as